Results 21 to 30 of about 4,559,139 (173)
The Microbiome and Uremic Solutes
Toxins, 2022 Uremic retention solutes, especially the protein-bound compounds, are toxic metabolites, difficult to eliminate with progressive renal functional decline.
Nadim Zaidan, Lama Nazzal
doaj +2 more sources
The Impact of CKD on Uremic Toxins and Gut Microbiota
Toxins, 2021 Numerous studies have indicated that the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD) is strictly associated with the accumulation of toxic metabolites in blood and other metabolic compartments.
Jacek Rysz +5 more
doaj +2 more sources
Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome
Toxins, 2018 Cardiovascular disease (CVD) is highly prevalent in the setting of chronic kidney disease (CKD). Such coexistence of CVD and CKD—the so-called “cardiorenal or renocardiac syndrome”—contributes to exponentially increased risk of ...
Suree Lekawanvijit
doaj +2 more sources
The Choice of Anti-Inflammatory Influences the Elimination of Protein-Bound Uremic Toxins. [PDF]
Toxins (Basel)Pain is a frequent and disturbing symptom among hemodialysis patients. Protein-bound uremic toxins (PBUTs) are related to cardiovascular and overall mortality, and they are difficult to remove with current hemodialysis treatments. The PBUT displacers, such as furosemide, tryptophan, or ibuprofen, may be promising new strategies for improving their ...
Escudero-Saiz VJ +10 more
europepmc +5 more sources
Binding Affinity and Capacity for the Uremic Toxin Indoxyl Sulfate [PDF]
Toxins, 2014 Protein binding prevents uremic toxins from removal by conventional extracorporeal therapies leading to accumulation in maintenance dialysis patients. Weakening of the protein binding may enhance the dialytic elimination of these toxins.
Eric Devine +4 more
doaj +2 more sources
Comprehensive Bibliometric Analysis of Uremic Toxin Research
ToxinsUremic toxins accumulate as kidney disease progresses, contributing to diverse systemic disorders. Despite numerous studies, no comprehensive mapping has been performed.
Marsuki Hardjo +4 more
doaj +2 more sources
Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis
ToxinsCardiovascular disease (CVD) frequently occurs in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. The mechanisms behind this may be related to traditional risk factors and CKD-specific factors that accelerate ...
Takuya Wakamatsu +3 more
doaj +2 more sources
Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence [PDF]
Toxins, 2022 Sodium–glucose cotransporter (SGLT) inhibitors are a class of oral hypoglycemic agents, which, in recent years, have been shown to improve renal and cardiovascular outcomes in patients with diabetic and non-diabetic chronic kidney disease.
Pieter Evenepoel +3 more
doaj +2 more sources
JACC: Basic to Translational ScienceSummary: Uremic cardiomyopathy has traditionally been attributed to pressure overload, volume overload, hypertension, and neurohormonal activation in chronic kidney disease.
Elchanan Parnasa, MD +5 more
doaj +2 more sources
Toxins, 2020 The protein-bound uremic toxins, indoxyl sulfate (IS) and p-cresyl sulfate (PCS), are considered to be harmful vascular toxins. Arterial media calcification, or the deposition of calcium phosphate crystals in the arteries, contributes significantly to ...
Britt Opdebeeck +2 more
doaj +2 more sources